NASDAQ:BCRX BioCryst Pharmaceuticals (BCRX) Stock Forecast, Price & News $6.42 -0.35 (-5.17%) (As of 10/3/2023 ET) Add Compare Share Share Today's Range$6.20▼$6.7750-Day Range$6.42▼$7.9252-Week Range$6.20▼$14.50Volume2.69 million shsAverage Volume2.77 million shsMarket Capitalization$1.22 billionP/E RatioN/ADividend YieldN/APrice Target$13.63 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability BioCryst Pharmaceuticals MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside112.2% Upside$13.63 Price TargetShort InterestBearish22.43% of Shares Sold ShortDividend StrengthN/ASustainability-1.85Upright™ Environmental ScoreNews Sentiment0.57Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.96) to ($0.48) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.26 out of 5 starsMedical Sector362nd out of 966 stocksBiological Products, Except Diagnostic Industry48th out of 144 stocks 4.5 Analyst's Opinion Consensus RatingBioCryst Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $13.63, BioCryst Pharmaceuticals has a forecasted upside of 112.2% from its current price of $6.42.Amount of Analyst CoverageBioCryst Pharmaceuticals has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 0.0 Short Interest Percentage of Shares Shorted22.43% of the outstanding shares of BioCryst Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverBioCryst Pharmaceuticals has a short interest ratio ("days to cover") of 16.9, which indicates bearish sentiment.Change versus previous monthShort interest in BioCryst Pharmaceuticals has recently increased by 2.91%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldBioCryst Pharmaceuticals does not currently pay a dividend.Dividend GrowthBioCryst Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreBioCryst Pharmaceuticals has received a 60.25% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Influenza medication", "Clinical research services for physical health", and "Hereditary angioedema medicine" products. See details.Environmental SustainabilityThe Environmental Impact score for BioCryst Pharmaceuticals is -1.85. Previous Next 2.0 News and Social Media Coverage News SentimentBioCryst Pharmaceuticals has a news sentiment score of 0.57. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for BioCryst Pharmaceuticals this week, compared to 3 articles on an average week.Search InterestOnly 10 people have searched for BCRX on MarketBeat in the last 30 days. This is a decrease of -41% compared to the previous 30 days.MarketBeat Follows6 people have added BioCryst Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, BioCryst Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.40% of the stock of BioCryst Pharmaceuticals is held by insiders.Percentage Held by Institutions91.46% of the stock of BioCryst Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for BioCryst Pharmaceuticals are expected to grow in the coming year, from ($0.96) to ($0.48) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of BioCryst Pharmaceuticals is -4.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of BioCryst Pharmaceuticals is -4.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here About BioCryst Pharmaceuticals (NASDAQ:BCRX) StockBioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor for complement-mediated diseases; and Galidesivir, to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.Read More BCRX Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BCRX Stock News HeadlinesOctober 3, 2023 | americanbankingnews.comTraders Purchase Large Volume of BioCryst Pharmaceuticals Put Options (NASDAQ:BCRX)September 26, 2023 | msn.comRBC Capital Reiterates Biocryst Pharmaceuticals (BCRX) Outperform RecommendationOctober 4, 2023 | Edge On The Street (Ad)The Strategic Gold Play You Haven't Heard AboutExperts recommend adding gold to your portfolio, but in what form? Some savvy investors are now rejecting coins and mining stocks in favor of a unique gold investment alternative. It holds explosive growth potential similar to a junior gold stock -- but with less risk exposure. September 26, 2023 | americanbankingnews.comBioCryst Pharmaceuticals (NASDAQ:BCRX) Given "Outperform" Rating at Royal Bank of CanadaSeptember 26, 2023 | msn.comBioCryst (BCRX) Surges 9.9%: Is This an Indication of Further Gains?September 18, 2023 | msn.comRBC Capital Upgrades Biocryst Pharmaceuticals (BCRX)September 18, 2023 | marketwatch.comBioCryst Pharmaceuticals Shares Rise 8% After Quebec's Approval of OrladeyoSeptember 18, 2023 | markets.businessinsider.comBioCryst (BCRX) was upgraded to a Buy Rating at RBC CapitalOctober 4, 2023 | Wall Street Fundamentals (Ad)Would Buffett Approve of This Growth Strategy?Warren Buffett's approach has been to find and invest in undervalued businesses with strong potential for growth. Taking this approach to heart and applying it to a Trillion Dollar industry has proved itself in a big way...achieving an incredible 400+% growth during a down market.September 18, 2023 | finance.yahoo.comINESSS Recommends Public Reimbursement for BioCryst’s ORLADEYO® (berotralstat) for the Prevention of Attacks for Hereditary Angioedema Patients in QuébecAugust 14, 2023 | seekingalpha.comAnalyzing BioCryst's Orladeyo Q2 Growth Amidst Competition And Liquidity HurdlesAugust 4, 2023 | msn.comRBC Capital Maintains Biocryst Pharmaceuticals (BCRX) Sector Perform RecommendationAugust 4, 2023 | msn.comHC Wainwright & Co. Reiterates Biocryst Pharmaceuticals (BCRX) Buy RecommendationAugust 4, 2023 | finance.yahoo.comBioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Q2 2023 Earnings Call TranscriptAugust 4, 2023 | markets.businessinsider.comH.C. Wainwright Keeps Their Buy Rating on BioCryst (BCRX)August 3, 2023 | finance.yahoo.comBioCryst Pharmaceuticals (BCRX) Q2 2023 Earnings Call TranscriptAugust 3, 2023 | markets.businessinsider.comHere's what Wall Street expects from BioCryst Pharmaceuticals's earningsAugust 3, 2023 | seekingalpha.comBioCryst Pharmaceuticals Q2 2023 Earnings PreviewAugust 3, 2023 | finance.yahoo.comBioCryst Reports Second Quarter 2023 Financial Results and Provides Business UpdateAugust 3, 2023 | seekingalpha.comBioCryst Pharmaceuticals, Inc. 2023 Q2 - Results - Earnings Call PresentationJuly 20, 2023 | finance.yahoo.comWall Street Analysts Think BioCryst (BCRX) Could Surge 107.2%: Read This Before Placing a BetJuly 20, 2023 | finance.yahoo.comBioCryst to Report Second Quarter 2023 Financial Results on August 3July 19, 2023 | finanznachrichten.deBioCryst Pharmaceuticals, Inc.: BioCryst Selects Er-Kim Pharmaceuticals as Commercial Partner for ORLADEYO (berotralstat) in TurkeyJuly 19, 2023 | finance.yahoo.comBioCryst Selects Er-Kim Pharmaceuticals as Commercial Partner for ORLADEYO® (berotralstat) in TurkeyJuly 18, 2023 | finance.yahoo.comInvesting in BioCryst Pharmaceuticals (NASDAQ:BCRX) three years ago would have delivered you a 40% gainJuly 17, 2023 | benzinga.comBioCryst to Participate in the 2023 US HAEA National SummitJuly 13, 2023 | msn.comB of A Securities Upgrades Biocryst Pharmaceuticals (BCRX)See More Headlines Receive BCRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioCryst Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address BCRX Company Calendar Last Earnings8/03/2023Today10/03/2023Next Earnings (Estimated)11/07/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:BCRX CUSIP09058V10 CIK882796 Webwww.biocryst.com Phone(919) 859-1302Fax919-859-1314Employees531Year Founded1986Price Target and Rating Average Stock Price Forecast$13.63 High Stock Price Forecast$30.00 Low Stock Price Forecast$10.00 Forecasted Upside/Downside+112.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($1.29) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-247,120,000.00 Net Margins-79.15% Pretax Margin-78.17% Return on EquityN/A Return on Assets-39.79% Debt Debt-to-Equity RatioN/A Current Ratio5.47 Quick Ratio5.18 Sales & Book Value Annual Sales$270.83 million Price / Sales4.49 Cash FlowN/A Price / Cash FlowN/A Book Value($1.58) per share Price / Book-4.06Miscellaneous Outstanding Shares189,490,000Free Float181,156,000Market Cap$1.22 billion OptionableOptionable Beta1.85 Social Links 10 Best Stocks to Own in 2023Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2023 and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Jon P. Stonehouse (Age 62)CEO, Pres & Exec. Director Comp: $1.15MMr. Anthony J. Doyle (Age 43)Sr. VP & CFO Comp: $726.42kMs. Alane P. Barnes (Age 57)Sr. VP, Chief Legal Officer & Corp. Sec. Comp: $655.33kDr. William P. Sheridan MBBS (Age 68)Chief Devel. Officer Comp: $784.09kDr. Yarlagadda S. Babu (Age 70)Chief Discovery Officer Comp: $691.45kDr. Helen M. Thackray FAAP (Age 55)M.D., Chief R&D Officer Comp: $844kMr. Charles K. Gayer (Age 52)Sr. VP & Chief Commercial Officer Comp: $643.43kMr. Michael L. Jones (Age 53)Exec. Director of Fin. & Principal Accounting Officer Mr. John D. Bluth (Age 50)Chief Communications Officer Ms. Stephanie AngeliniChief People OfficerMore ExecutivesKey CompetitorsNovavaxNASDAQ:NVAXAgenusNASDAQ:AGENHalozyme TherapeuticsNASDAQ:HALOSpringWorks TherapeuticsNASDAQ:SWTXVir BiotechnologyNASDAQ:VIRView All CompetitorsInsiders & InstitutionsWolverine Trading LLCSold 9,100 shares on 8/23/2023Ownership: 0.000%Virginia Retirement Systems ET ALBought 80,600 shares on 8/22/2023Ownership: 0.043%Osaic Holdings Inc.Bought 41,028 shares on 8/21/2023Ownership: 0.318%California State Teachers Retirement SystemSold 3,905 shares on 8/21/2023Ownership: 0.121%GTS Securities LLCBought 18,300 shares on 8/16/2023Ownership: 0.010%View All Insider TransactionsView All Institutional Transactions BCRX Stock - Frequently Asked Questions Should I buy or sell BioCryst Pharmaceuticals stock right now? 7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for BioCryst Pharmaceuticals in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" BCRX shares. View BCRX analyst ratings or view top-rated stocks. What is BioCryst Pharmaceuticals' stock price forecast for 2023? 7 analysts have issued twelve-month price targets for BioCryst Pharmaceuticals' stock. Their BCRX share price forecasts range from $10.00 to $30.00. On average, they anticipate the company's share price to reach $13.63 in the next twelve months. This suggests a possible upside of 112.2% from the stock's current price. View analysts price targets for BCRX or view top-rated stocks among Wall Street analysts. How have BCRX shares performed in 2023? BioCryst Pharmaceuticals' stock was trading at $11.48 on January 1st, 2023. Since then, BCRX shares have decreased by 44.1% and is now trading at $6.42. View the best growth stocks for 2023 here. When is BioCryst Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 7th 2023. View our BCRX earnings forecast. How were BioCryst Pharmaceuticals' earnings last quarter? BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced its quarterly earnings results on Thursday, August, 3rd. The biotechnology company reported ($0.24) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.25) by $0.01. The biotechnology company had revenue of $81.01 million for the quarter, compared to the consensus estimate of $81.42 million. BioCryst Pharmaceuticals's quarterly revenue was up 24.2% compared to the same quarter last year. During the same period last year, the firm posted ($0.32) EPS. What ETFs hold BioCryst Pharmaceuticals' stock? ETFs with the largest weight of BioCryst Pharmaceuticals (NASDAQ:BCRX) stock in their portfolio include iShares Genomics Immunology and Healthcare ETF (IDNA), ETFMG Treatments Testing and Advancements ETF (GERM) and Virtus LifeSci Biotech Products ETF (BBP).ALPS Medical Breakthroughs ETF (SBIO). What is Jon P. Stonehouse's approval rating as BioCryst Pharmaceuticals' CEO? 9 employees have rated BioCryst Pharmaceuticals Chief Executive Officer Jon P. Stonehouse on Glassdoor.com. Jon P. Stonehouse has an approval rating of 40% among the company's employees. This puts Jon P. Stonehouse in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. 64.0% of employees surveyed would recommend working at BioCryst Pharmaceuticals to a friend. What other stocks do shareholders of BioCryst Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other BioCryst Pharmaceuticals investors own include Inovio Pharmaceuticals (INO), El Pollo Loco (LOCO), Advanced Micro Devices (AMD), Idera Pharmaceuticals (IDRA), OPKO Health (OPK), Dynavax Technologies (DVAX), La Jolla Pharmaceutical (LJPC), Novavax (NVAX), Sorrento Therapeutics (SRNE) and VBI Vaccines (VBIV). What is BioCryst Pharmaceuticals' stock symbol? BioCryst Pharmaceuticals trades on the NASDAQ under the ticker symbol "BCRX." How do I buy shares of BioCryst Pharmaceuticals? Shares of BCRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is BioCryst Pharmaceuticals' stock price today? One share of BCRX stock can currently be purchased for approximately $6.42. How much money does BioCryst Pharmaceuticals make? BioCryst Pharmaceuticals (NASDAQ:BCRX) has a market capitalization of $1.22 billion and generates $270.83 million in revenue each year. The biotechnology company earns $-247,120,000.00 in net income (profit) each year or ($1.29) on an earnings per share basis. How many employees does BioCryst Pharmaceuticals have? The company employs 531 workers across the globe. How can I contact BioCryst Pharmaceuticals? BioCryst Pharmaceuticals' mailing address is 4505 EMPEROR BOULEVARD SUITE 200, DURHAM NC, 27703. The official website for the company is www.biocryst.com. The biotechnology company can be reached via phone at (919) 859-1302, via email at investorrelations@biocryst.com, or via fax at 919-859-1314. This page (NASDAQ:BCRX) was last updated on 10/4/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioCryst Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.